Global Gene Therapy Market Analysis & Forecast to 2022: $350+ Million Market Strengthened by Recent Approvals of Kymriah, Yescarta and Luxturna in the US
March 07, 2018 06:57 ET
|
Research and Markets
Dublin, March 07, 2018 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Market Analysis & Forecast to 2022" report has been added to ResearchAndMarkets.com's offering. The global...
BioCanCell Presents Final Data from Its Phase 2 Study of BC-819 for Early Stage Bladder Cancer at the 2018 ASCO Genitourinary Cancers Symposium
February 09, 2018 15:15 ET
|
BioCanCell, Ltd.
BC-819 demonstrates meaningful activity Two registrational studies planned to be initiated in 2018 CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a...
BioCanCell Announces Terms of $25 Million Funding Round
January 23, 2018 08:00 ET
|
BioCanCell Ltd.
JERUSALEM, Jan. 23, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL) (the “Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Shareholders Turn Down Tender Offer to Take BioCanCell Private
December 28, 2017 09:23 ET
|
BioCanCell Ltd.
JERUSALEM, Dec. 28, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round
December 11, 2017 16:01 ET
|
BioCanCell Ltd.
JERUSALEM, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer
November 15, 2017 16:01 ET
|
BioCanCell Ltd.
JERUSALEM, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update
October 30, 2017 07:00 ET
|
BioCancell Ltd.
JERUSALEM, Oct. 30, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
BioCanCell Announces Appointment of Ms. Ruti Alon to Board of Directors
August 14, 2017 07:00 ET
|
BioCancell Ltd.
JERUSALEM, Aug. 14, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to...
Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026: Focus on Lentivirus, AAV, Adenovirus, Retrovirus and Plasmid DNA
December 21, 2016 05:14 ET
|
Research and Markets
Dublin, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026" report to their...
Cancer Gene Therapy Market size to exceed $4.3bn by 2024: Global Market Insights Inc.
September 13, 2016 07:00 ET
|
Global Market Insights
Ocean View, Delaware, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Cancer Gene Therapy Market size was USD 805.5 million in 2015, with 20.7% CAGR estimation from 2016 to 2024; as per a new research report...